60 Degrees Pharmaceuticals (SXTP) Total Non-Current Liabilities (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Total Non-Current Liabilities of $143197.0 for Q1 2026, down 2.26% year-over-year from $146502.0 in Q1 2025, and down 0.56% quarter-over-quarter from $144003.0 in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Total Non-Current Liabilities for 5 consecutive years, with $143197.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 2.26% year-over-year to $143197.0; the TTM figure through Mar 2026 stood at $143197.0 (down 2.26% YoY), while the FY2025 annual figure was $144003.0, down 2.12% from the prior year.
- Total Non-Current Liabilities slipped to $143197.0 in Q1 2026 per SXTP's latest filing, from $144003.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $1.5 million in Q4 2022 and bottomed at -$1.5 million in Q1 2023.
- Historically, Total Non-Current Liabilities has averaged $215616.4 across 5 years, with a median of $147507.0 in 2024.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities sank 90.15% — and 2024, when it soared 109.97%.
- 60 Degrees Pharmaceuticals' Total Non-Current Liabilities stood at $1.5 million in 2022, then tumbled by 90.15% to $150251.0 in 2023, then fell by 2.08% to $147119.0 in 2024, then dropped by 2.12% to $144003.0 in 2025, then slipped by 0.56% to $143197.0 in 2026.
- Business Quant data shows SXTP's Total Non-Current Liabilities at $143197.0 in Q1 2026, $144003.0 in Q4 2025, and $144992.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.54 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 59.41 Bn | 54.27 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | 9.32 Bn |
| 10 | 60 Degrees Pharmaceuticals | 2.95 Mn | 1.92 Mn | 56,798.00 | 149,176.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 143,197.00 |
| Dec 31, 2025 | 144,003.00 |
| Sep 30, 2025 | 144,992.00 |
| Jun 30, 2025 | 145,477.00 |
| Mar 31, 2025 | 146,502.00 |
| Dec 31, 2024 | 147,119.00 |
| Sep 30, 2024 | 147,895.00 |
| Jun 30, 2024 | 148,670.00 |
| Mar 31, 2024 | 149,460.00 |
| Dec 31, 2023 | 150,251.00 |
| Sep 30, 2023 | 152,594.00 |
| Jun 30, 2023 | 1.37 Mn |
| Mar 31, 2023 | -1.50 Mn |
| Dec 31, 2022 | 1.53 Mn |